Neurology Letters最新文献_第2页

The Interplay Between the Gut Microbiome and Neurological Disorders: Exploring the Gut-Brain Axis 肠道微生物群与神经系统疾病之间的相互作用:探索肠-脑轴

Neurology Letters Pub Date : 2023-04-01 DOI: 10.52547/nl.2.1.25

S. Pang, Jing Wen-Yi, Wu Zi

引用次数: 1

Guillain-Barré syndrome in remission of Ulcerative colitis: a case report 溃疡性结肠炎缓解期格林-巴罗综合征1例报告

Neurology Letters Pub Date : 2023-04-01 DOI: 10.52547/nl.2.1.13

Maedeh Khodkam, Delaram Panahi

引用次数: 0

COVID-19 vaccine-hesitancy is associated with lower cortical volume in elderly individuals 在老年人中，COVID-19疫苗犹豫与皮质体积较低有关

Neurology Letters Pub Date : 2023-04-01 DOI: 10.52547/nl.2.1.35

F. Nabizadeh

引用次数: 0

Current understanding of the association between Amyotrophic lateral sclerosis and frontotemporal dementia: Letter to Editor 目前对肌萎缩侧索硬化症和额颞叶痴呆之间关系的理解:致编辑的信

Neurology Letters Pub Date : 2023-04-01 DOI: 10.52547/nl.2.1.42

J Zhang, Hairui Wang

引用次数: 0

Quantitative Electroencephalography Findings in Treatment-resistant and Responsive Patients with Idiopathic Generalized Tonic-Clonic Epilepsy 特发性全身性强直阵挛性癫痫患者治疗抵抗性和反应性的定量脑电图表现

Neurology Letters Pub Date : 2023-04-01 DOI: 10.52547/nl.2.1.6

S. Shaafi, Seyede Maryam Nasibi, Gholamreza Chalabianloo, S. A. Nejadghaderi

{"title":"Quantitative Electroencephalography Findings in Treatment-resistant and Responsive Patients with Idiopathic Generalized Tonic-Clonic Epilepsy","authors":"S. Shaafi, Seyede Maryam Nasibi, Gholamreza Chalabianloo, S. A. Nejadghaderi","doi":"10.52547/nl.2.1.6","DOIUrl":"https://doi.org/10.52547/nl.2.1.6","url":null,"abstract":"Background: With roughly 50 million people affected in the world, epilepsy is a particularly important disorder of the brain commonly diagnosed based on findings of quantitative electroencephalography (QEEG). The present investigation was aimed to evaluate differences in QEEG readings of drug-resistant and drug-responsive patients with idiopathic generalized epilepsy (IGE) with tonic-clonic seizures in a northwestern Iranian population. Methods: A total of 60 participants, consisting of 30 drug-resistant and 30 drug-responsive patients with IGE, were enrolled. Data, including demographic information and Z-transformed absolute power values of QEEG in anterior, central and posterior alpha, beta, delta and theta bands were collected. The analysis was conducted using IBM SPSS and a p-value<0.05 was considered as statistically significant. Results: Of the 60 participants with a mean age of 31.55 ± 10.48, 41 (68.3%) were female and 19 (31.7%) were male. Statistically significant differences were observed in anterior alpha, beta and theta bands, central alpha, beta, delta and theta bands, and posterior beta, delta and theta bands between the two groups, with the absolute power Z-scores of drug-resistant groups being significantly higher than the other (P-values<0.05). Abnormal EEGs were recorded for 16 (53.3%) and 5 (23.8%) patients from the drug-resistant and drug-response groups, respectively, indicating a significant difference (P-value=0.006). Female patients were more likely to have drug-resistant disease than male participants (P-value=0.003). Conclusions: QEEGs with normal readings indicate a more favorable prognosis, compared with those containing abnormal findings.","PeriodicalId":208931,"journal":{"name":"Neurology Letters","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114269920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Review Current and Emerging Treatment Options for Alzheimer's Disease 回顾阿尔茨海默病目前和新出现的治疗方案

Neurology Letters Pub Date : 2023-04-01 DOI: 10.52547/nl.2.1.1

Dimple Kumar Vats, Nistara Biswas, Preethi Pandian, Anupam Kamalakannan

{"title":"Review Current and Emerging Treatment Options for Alzheimer's Disease","authors":"Dimple Kumar Vats, Nistara Biswas, Preethi Pandian, Anupam Kamalakannan","doi":"10.52547/nl.2.1.1","DOIUrl":"https://doi.org/10.52547/nl.2.1.1","url":null,"abstract":"Alzheimer's disease (AD) is a progressive neurodegenerative disorder that affects cognitive function, memory, and behavior. Currently, available treatments for AD primarily focus on managing symptoms, rather than addressing the underlying disease process. However, there is ongoing research and development in the field of AD treatment, with the hope of finding new and more effective therapies. Medications, such as cholinesterase inhibitors and NMDA receptor antagonists, are primarily used to treat cognitive symptoms of the disease. Non-pharmacological interventions, such as cognitive and memory training, occupational therapy, social and recreational activities, and environmental modifications, can also play a significant role in managing the symptoms of AD. Emerging treatments for AD include drugs that target beta-amyloid and tau protein, stem cell-based therapies, non-invasive brain stimulation techniques, and dietary and lifestyle interventions. The results of ongoing clinical trials will provide important information on the safety and efficacy of these treatments and will help to guide future research. It is important to note that while there are promising developments in the field, more research is needed to fully understand the underlying causes of AD and to develop effective treatments. This paper provides an overview of current and emerging treatments for AD. It discusses the role of medications, non-pharmacological interventions, and emerging treatments in managing the symptoms of AD. It also provides an update on the latest emerging treatments for AD, including drugs that target beta-amyloid and tau protein, stem cell-based therapies, non-invasive brain stimulation techniques, and dietary and lifestyle interventions. The paper concludes by emphasizing the need for further research and development in the field of AD treatment.","PeriodicalId":208931,"journal":{"name":"Neurology Letters","volume":"38 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117275302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Regional cerebral blood flow and brain atrophy in mild cognitive impairment and Alzheimer's disease 轻度认知障碍和阿尔茨海默病的局部脑血流和脑萎缩

Neurology Letters Pub Date : 2023-04-01 DOI: 10.52547/nl.2.1.16

F. Nabizadeh, M. Balabandian, M. Rostami, Soraya Mehrabi, Mohsen Sedighi

引用次数: 0

Antioxidant supplements and cognition in Multiple Sclerosis: a systematic review 抗氧化剂补充剂与多发性硬化症的认知:一项系统综述

Neurology Letters Pub Date : 2022-12-30 DOI: 10.52547/nl.1.2.48

F. Nabizadeh, F. Sodeifian, A. Ghaderi, Amir Mohammad Sharafi, M. Balabandian

引用次数: 0

Neurology Letters is born! 《神经病学通讯》诞生了!

Neurology Letters Pub Date : 2022-12-01 DOI: 10.52547/nl.1.2.47

F. Nabizadeh, Z. Mirzaasgari